Wa'el Hashad
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
October 09, 2024 09:05 ET | Longeveron
Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society Mtg.
Longeveron Logo.jpg
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
October 07, 2024 09:05 ET | Longeveron
Wa’el Hashad, Chief Executive Officer of Longeveron, will participate in a Fireside Chat at the UBS Virtual Organ Restoration and Cell Therapy Day Oct 15th
Longeveron Logo.jpg
Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
October 02, 2024 09:05 ET | Longeveron
Longeveron management to present at the ROTH Healthcare Opportunities Conference. Speaking on Emerging Frontiers in Neuroscience panel and hosting 1x1s.
Longeveron Logo.jpg
Longeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
September 26, 2024 09:05 ET | Longeveron
Longeveron to attend Cell & Gene Meeting on the Mesa to highlight its cellular therapy program in Alzheimer's disease and CDMO facilities and services.
Wa'el Hashad
Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)
September 03, 2024 09:00 ET | Longeveron
Longeveron announces positive Type C meeting with FDA, clarifying regulatory pathway to BLA submission for Lomecel-B for hypoplastic left heart syndrome.
Longeveron Logo.jpg
Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 26, 2024 16:05 ET | Longeveron
Longeveron to present at HC Wainwright global investment conference.
Wa'el Hashad
Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024 16:05 ET | Longeveron
Longeveron reports Q2 2024 financial results and provides business update. Phase 2b clinical trial in HLHS achieves 70% enrollment.
Longeveron Logo.jpg
Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
August 05, 2024 16:05 ET | Longeveron
Longeveron announced that it will report Q2 2024 financial results and provide a business update on Wednesday, August 14, 2024.
Nataliya Agafonova
Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)
July 28, 2024 16:51 ET | Longeveron
Longeveron Phase 2a clinical results in Alzheimer's Disease selected for Featured Research oral presentation at Alzheimer’s Association International Conf
Longeveron Logo.jpg
Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
July 19, 2024 16:05 ET | Longeveron
Longeveron announces closing of previously announced registered direct offering, raising $9 million in gross proceeds.